Business Wire

New SunTech Medical CT40 Vital Signs Device to Feature Masimo SET® Pulse Oximetry Technology

Del

Masimo (NASDAQ: MASI) and SunTech Medical, a Halma (LSE:HLMA) company, jointly announced today the integration of Masimo SET® pulse oximetry technology into SunTech’s CT40, a next generation spot-check vital signs device.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160623005340/en/

Masimo Signal Extraction Technology (SET®) Measure-through Motion and Low Perfusion™ pulse oximetry measures oxygen saturation (SpO2), pulse rate, and perfusion index. Masimo SET® has been shown to significantly reduce false alarms and accurately monitor for true alarms1,2 and is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world.

The SunTech CT40 is an ideal, affordable solution for clinical-grade spot-check measurements of blood pressure, temperature and pulse oximetry in hospitals and clinics. Ambulatory care, long-term care and low-acuity hospital departments can easily implement this versatile, user-friendly vital signs device that offers both advanced features and digital connectivity. The modular design allows clinicians to easily make adaptations to the device while in the field, adding thermometry, SpO2 and Wi-Fi as needed. Other advanced features include the ability to transmit measurement data directly from the device, in accordance with HL7 messaging protocols, as well as BP Averaging Mode—an increasingly important component of accurate blood pressure measurement, as evidenced by the recently published SPRINT Study from the National Institutes of Health (NIH), which specified that a mean of three office BP measurements would be used to establish target BPs for Standard Group participants.3

“Both SunTech and Masimo share industry-leading technologies within our respective areas of expertise,” said Kenny Andersen, VP of Strategic Product Development at SunTech Medical. “Partnering with them on our next-generation vital signs platform is a very natural strategy. Masimo SET pulse oximetry is the benchmark for clinical performance, just as SunTech Advantage technology is for blood pressure. We look forward to a long and successful partnership.”

Rick Fishel, Masimo’s President of Worldwide OEM Business and Strategic Development, stated, “SunTech Medical is a recognized global leader and worldwide supplier of non-invasive blood pressure measurement technology. Combining best-in-class measurement technologies that provide superior performance, accuracy, and affordability, in flexible and cost effective monitors, supports our organizations’ mutual vision to offer solutions that help clinicians improve patient outcomes and reduce the cost of healthcare delivery. We are very pleased to partner with SunTech Medical and that Masimo SET pulse oximetry is the preferred pulse oximetry offering in the highly versatile and cost-effective SunTech CT40 monitor.”

The SunTech CT 40 with Masimo SET® technology has a CE Mark. It is not FDA cleared and is not available for sale in the United States.

@MasimoInnovates | #Masimo

 

1.

Shah N, Ragaswamy HB, Govindugari K, Estanol L "Performance of Three New-Generation Pulse Oximeters during Motion and Low Perfusion in Volunteers" .J Clin Anesth. 2012 Aug;24(5):385-91.

2.

Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology, February 2010, Vol. 112, Issue 2.

3.

The SPRINT Study Research Group; The design and rationale of a multi-center clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT); Clin Trials; October 2014; 11(5): 532-546.
 

About SunTech Medical

SunTech Medical, a Halma company, has been the preeminent supplier of clinical-grade blood pressure monitoring products and technologies for nearly 30 years. More than 75 companies trust SunTech Medical's OEM non-invasive blood pressure solutions for their patient monitoring needs. SunTech Medical produces the leading cardiac stress test blood pressure monitor and is the world's foremost manufacturer of ambulatory blood pressure monitoring products. SunTech Medical also offers solutions for in-office blood pressure monitoring as well as a complete line of blood pressure cuffs designed for general and specific applications.

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect™ (MOC-9™) interface. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential benefits of Masimo’s SET® pulse oximetry technology into SunTech’s CT 40. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo’s SET® pulse oximetry technology, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Contact information

Masimo
Irene Paigah, 858-859-7001
irenep@masimo.com
or
SunTech Medical
Elliott Holloway, 919-654-2366
eholloway@suntechmed.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Tempo Grows Revenue by 38% in 2017 to $17.9 Million19.2.2018 11:14Pressemelding

Tempo, creator of efficiency-enhancing project management software solutions for Atlassian’s Jira platform, announced strong results for its 2017 fiscal year ending December 31, 2017. “2017 marks another productive and successful year for Tempo, with December our highest grossing month ever and sales across our product range exceeding expectations,” commented Agust Einarsson, CEO, “The completion of our new cloud infrastructure and successful migration of our entire customer base to Amazon Web Services (AWS) marks a strategic milestone, empowering Tempo with a more scalable underlying platform and enabling us to deploy products to customers faster.” Highlights for 2017 include: Revenue grew 38% year-over-year to US$17.9 million Almost 2,000 new customers were acquired Launched our new cloud infrastructure Expanded product footprint beyond the Atlassian environment with Tempo for Slack North American operations continued to grow More than 120 partners worldwide Celebrated our 10-year an

Morrow Sodali Announces Appointment of David Shammai as Corporate Governance Director - Cross Border19.2.2018 10:05Pressemelding

Morrow Sodali today announced that David Shammai has joined the firm as Corporate Governance Director - Cross Border. David joins from APG Asset Management, the Dutch pension fund manager, where in his role as senior corporate governance specialist he was involved in voting, policy, and engagement. Based in the London office, David will focus on the firm’s growing corporate governance activities across its European offices. Together with Morrow Sodali’s expanding team of corporate governance professionals, David will work to further develop the firm’s governance services – ranging from benchmarking and assessments of governance practice to board advisory on engagement with investors. “At Morrow Sodali we recognise that today many of our clients face growing needs for an in-depth and meaningful dialogue with their investors on a broadening range of topics. Having David onboard - from one of the world’s largest fiduciary asset managers - demonstrates our reinforced commitment to helping

MagicStay Expands Its Signature Series with onefinestay19.2.2018 09:09Pressemelding

MagicStay.com , the apartment rental platform for business travelers, is expanding its upscale offering by distributing onefinestay apartments. MagicStay's Signature® range features a selection of upscale and design apartments, managed by professional agencies that pay particular attention to the quality of hospitality and services offered. onefinestay, the world’s leading luxury private rental brand, is positioned in the 4 and 5 star range that can appeal to a business clientele. onefinestay is renowned in the hospitality industry for its high-touch service, which is always curated to each guest and stay. The company, which joined the AccorHotels group in 2016 offers a peace of mind promise which meets MagicStay’s quality and safety criteria. More than 1,000 homes from onefinestay's portfolio in popular business destinations such as London, Paris, New York or Los Angeles complete the MagicStay Signature® range, offering distinctive and authentic accommodation in city centres. Business

GSMA Announces Winners of Inaugural Mobile World Scholar Challenge19.2.2018 09:00Pressemelding

The GSMA today announced the winners of its inaugural Mobile World Scholar Challenge. New for Mobile World Congress 2018, the Mobile World Scholar Challenge is a video-based competition designed to discover and highlight ground-breaking new technologies developed at universities around the globe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180219005023/en/ GSMA Submitted Photo “Embracing new ideas is the key to innovation and growth, be it an economy, an industry, a company, charity or individual,” said John Hoffman, CEO, GSMA Ltd. “At Mobile World Congress, we are constantly looking to showcase cutting-edge ideas poised to impact the mobile world, and the winners of this first Mobile World Scholar Challenge certainly represent this. Our congratulations to all of the winners, as well as everyone who submitted their innovations for consideration.” Challenge participants submitted short-form videos that promote the science b

Reply 2018 Code Challenge: Join Us19.2.2018 09:00Pressemelding

On 15th March 2018 Reply will launch the first Reply Code Challenge, focused on team programming and open to students and professional coders. All the participant teams who have registered on challenges.reply.com will face the challenge of solving a logical math problem through coding. The idea for code challenges came from the “Reply Code Master Team”, a group of Reply developers passionate about coding competitions and design. After a first internal round involving Replyers, Reply is now opening the challenge up to the world. It’s all about learning together and the fun of competition. Reply believes and invests in talent scouting and lifelong learning. The Reply Code Challenge initiative is part of Reply’s ongoing efforts to promote coding to young people (i.e.: The Code for Kids program that involved more than 15,000 girls and boys among 6-18 years in Europe in the last 24 months) to businesses and geeks. Sign up on challenges.reply.com from 15th February, create a team, and connec

New Data Demonstrates Long-Term Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis Treated with Janssen’s TREMFYA® (guselkumab)19.2.2018 08:00Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA® (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.1 Findings from the study also demonstrated that a vast majority of patients originally randomised to guselkumab, but withdrawn from treatment at week 28, regained a PASI 90 response within six months of initiating guselkumab retreatment.1 These long-term findings from the Phase III VOYAGE 2 study were presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, during a late-breaking abstract session at 1:00 PM PST (22:00 CET) on Saturday 17 February. “The longer-term data from VOYAGE 2 shows promising results for guselkumab as both a continuous, long-term treatment for mod